Investigation into the use of radiofrequency ablation for the treatment of watermelon stomach

RadioFrequency Ablation for Gastric Antral Vascular Ectasia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN13565602

Enrollment

Registered

2016-06-14

Start date

2015-09-01

Completion date

Unknown

Last updated

2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric antral vascular ectasia (GAVE) Circulatory System Gastric antral vascular ectasia (GAVE)

Interventions

All patients receive radiofrequency ablation (RFA) for the treatment of gastric antral vascular ectasia (GAVE) coupled with standard care. The usual care pathway involves regular blood tests to assess

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Existing diagnosis of GAVE that has resulted in anaemia requiring either intravenous iron replacement or blood transfusion 2. Undergoing endoscopic treatment with RFA 3. Aged 18 years and over

Exclusion criteria

Exclusion criteria: 1. Active malignancy 2. Anaemia due to other cause such as coeliac disease, small bowel pathology or haematological disease 3. Pregnancy

Design outcomes

Primary

Measure	Time frame
1. Quality of life is measured using the Functional Assessment of Chronic Illness Therapy - fatigue scale (FACIT-F) questionnaire at baseline (pre-RFA) and 6 months post-RFA 2. Number of red blood cell (RBC) packs transfused (transfusion requirement), parenteral iron requirements and haemoglobin concentrations (g/dL) are measured by reviewing patient notes and blood tests at baseline (pre-RFA) and 6 months post-RFA	—

Measure

Time frame

1. Quality of life is measured using the Functional Assessment of Chronic Illness Therapy - fatigue scale (FACIT-F) questionnaire at baseline (pre-RFA) and 6 months post-RFA 2. Number of red blood cell (RBC) packs transfused (transfusion requirement), parenteral iron requirements and haemoglobin concentrations (g/dL) are measured by reviewing patient notes and blood tests at baseline (pre-RFA) and 6 months post-RFA

—

Secondary

Measure	Time frame
1. Number of endoscopy treatment sessions are measured by reviewing patient notes at baseline (pre-RFA) and 6 months post-RFA 2. Percentage surface regression in macroscopically evident GAVE is measured during endoscopy at any follow up endoscopy in the 6 months post-treatment	—

Countries

United Kingdom

Contacts

Public ContactRehan Haidry

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026